ZEB1 and c-Jun levels contribute to the establishment of highly lytic Epstein-Barr virus infection in gastric AGS cells

Journal of Virology

Volumn 81, Issue 18, 2007, Pages 10113-10122

  Feng, Wen Hai ^a   Kraus, Richard J ^b   Dickerson, Sarah J ^b   Hui, Jun Lim ^b   Jones, Richard J ^a   Yu, Xianming ^b   Mertz, Janet E ^b   Kenney, Shannon C ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; IMMEDIATE EARLY PROTEIN BZLF1; PROTEIN C JUN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ZEB1; UNCLASSIFIED DRUG; VIRUS PROTEIN; HOMEODOMAIN PROTEIN; MADS DOMAIN PROTEIN; MEF2D PROTEIN, HUMAN; MYOGENIC FACTOR; REPRESSOR PROTEIN; ZEB1 PROTEIN, HUMAN;

ARTICLE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; HELA CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; LYSIS; MUTATIONAL ANALYSIS; PLASMID; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CARCINOMA; VIRUS INFECTION; COMPARATIVE STUDY; GENETICS; METABOLISM; MUTATION; PHOSPHORYLATION; PROMOTER REGION; PROTEIN MOTIF; STOMACH TUMOR; VIROLOGY;

HUMAN HERPESVIRUS 4;

AMINO ACID MOTIFS; EPSTEIN-BARR VIRUS INFECTIONS; HELA CELLS; HERPESVIRUS 4, HUMAN; HOMEODOMAIN PROTEINS; HUMANS; MADS DOMAIN PROTEINS; MUTATION; MYOGENIC REGULATORY FACTORS; PHOSPHORYLATION; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-JUN; REPRESSOR PROTEINS; STOMACH NEOPLASMS; TRANSCRIPTION FACTORS; VIRAL REGULATORY PROTEINS;

EID: 35348896613     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00692-07     Document Type: Article

References (67)

1. Adamson, A. L., and S. C. Kenney. 1998. Rescue of the Epstein-Barr virus BZLF1 mutant Z(S186A), early gene activation defect by the BRLF1 gene product. Virology 251:187-197.
2. Adler, B., E. Schaadt, B. Kempkes, U. Zimber-Strobl, B. Baier, and G. W. Bornkamm. 2002. Control of Epstein-Barr virus reactivation by activated CD40 and viral latent membrane protein 1. Proc. Natl. Acad. Sci. USA 99:437-442.
3. Alizadeh, A. A., M. B. Eisen, R. E. Davis, et al. 2000. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511.
4. Ambinder, R. F., K. D. Robertson, S. M. Moore, and J. Yang. 1996. Epstein-Barr virus as a therapeutic target in Hodgkin's disease and nasopharyngeal carcinoma. Semin. Cancer Biol. 7:217-226.
5. Babcock, G. J., L. L. Decker, M. Volk, and D. A. Thorley-Lawson. 1998. EBV persistence in memory B cells in vivo. Immunity 9:395-404.
6. Borras, A. M., J. L. Strominger, and S. H. Speck. 1996. Characterization of the ZI domains in the Epstein-Barr virus BZLF1 gene promoter: role in phorbol ester induction. J. Virol. 70:3894-3901.
7. Bryant, H., and P. J. Farrell. 2002. Signal transduction and transcription factor modification during reactivation of Epstein-Barr virus from latency. J. Virol. 76:10290-10298.
8. Cahir-McFarland, E. D., K. Carter, A. Rosenwald, J. M. Giltnane, S. E. Henrickson, L. M. Staudt, and E. Kieff. 2004. Role of NF-κB in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells. J. Virol. 78:4108-4119.
9. Chevallier-Greco, A., E. Manet, P. Chavrier, C. Mosnier, J. Daillie, and A. Sergeant. 1986. Both Epstein-Barr virus (EBV)-encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an EBV early promoter. EMBO J. 5:3243-3249.
10. Chua, H. L., P. Bhat-Nakshatri, S. E. Clare, A. Morimiya, S. Badve, and H. Nakshatri. 2007. NF-κB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene 26:711-724.
11. Countryman, J., H. Jenson, R. Seibel, H. Wolf, and G. M. Miller. 1987. Polymorphic proteins encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency. J. Virol. 61:3672-3679.
12. Darr, C. D., A. Mauser, and S. Kenney. 2001. Epstein-Barr virus immediate early protein BRLF1 induces the lytic form of viral replication through a mechanism involving phosphatidylinositol-3 kinase activation. J. Virol. 75: 6135-6142.
13. Delecluse, H.-J., T. Hilsendegen, D. Pich, R. Zeidler, and W. Hammerschmidt. 1998. Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells. Proc. Natl. Acad. Sci. USA 95:8245-8250.
14. Feederle, R., M. Kost, M. Baumann, A. Janz, E. Drouet, W. Hammerschmidt, and H. J. Delecluse. 2000. The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J. 19:3080-3089.
15. Feng, W.-H., G. Hong, H.-J. Delecluse, and S. C. Kenney. 2004. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J. Virol. 78: 1893-1902.
16. Feng, W.-H., B. Israel, N. Raab-Traub, P. Busson, and S. C. Kenney. 2002. Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Res. 62:1920-1926.
17. Feng, W.-H., and S. C. Kenney. 2006. Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. Cancer Res. 66:8762-8769.
18. Feng, W.-H., E. Westphal, A. Mauser, N. Raab-Traub, M. L. Gulley, P. Busson, and S. C. Kenney. 2002. Use of adenovirus vectors expressing Epstein-Barr virus (EBV) immediate-early protein BZLF1 or BRLF1 to treat EBV-positive tumors. J. Virol. 76:10951-10959.
19. Flemington, E., and S. H. Speck. 1990. Identification of phorbol ester response elements in the promoter of Epstein-Barr virus putative lytic switch gene BZLF1. J. Virol. 64:1217-1226.
20. Genetta, T., D. Ruezinsky, and T. Kadesch. 1994. Displacement of an E-box-binding repressor by basic helix-loop-helix proteins: implications for B-cell specificity of the immunoglobulin heavy-chain enhancer. Mol. Cell. Biol. 14:6153-6163.
21. Gorman, C. M., L. F. Moffat, and B. H. Howard. 1982. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol. Cell. Biol. 2:1044-1051.
22. Gray, S., and M. Levine. 1996. Transcriptional repression in development. Curr. Opin. Cell Biol. 8:358-364.
23. Gregoire, S., and X.-J. Yang. 2005. Association with class IIa histone deacetylases upregulates the sumoylation of MEF2 transcription factors. Mol. Cell. Biol. 25:2273-2287.
24. Gruffat, H., E. Manet, A. Rigolet, and A. Sergeant. 1990. The enhancer factor R of Epstein-Barr virus (EBV) is a sequence-specific DNA binding protein. Nucleic Acids Res. 18:6835-6843.
25. Gruffat, H., E. Manet, and A. Sergeant. 2002. MEF2-mediated recruitment of class II HDAC at the EBV immediate early gene BZLFI links latency and chromatin remodeling. EMBO Rep. 3:141-146.
26. Hardwick, J. M., P. M. Lieberman, and S. D. Hayward. 1988. A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early anti-gen. J. Virol. 62:2274-2284.
27. Hildesheim, A., and P. H. Levine. 1993. Etiology of nasopharyngeal carcinoma: a review. Epidemiol. Rev. 15:466-485.
28. Hong, G. K., M. L. Gulley, W. H., Feng, H.-J. Delecluse, E. Holley-Guthrie, and S. C. Kenney. 2005. Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model. J. Virol. 79:13993-14003.
29. Hording, U., H. W. Nielsen, H. Albeck, and S. Daugaard. 1993. Nasopharyngeal carcinoma: Histopathological types and association with Epstein-Barr virus. Eur. J. Cancer B Oral Oncol. 29:137-139.
30. Huang, J., G. Liao, H. Chen, F. Y. Wu, L. Hutt-Fletcher, G. S. Hayward, and S. D. Hayward. 2006. Contribution of C/EBP proteins to Epstein-Barr virus lytic gene expression and replication in epithelial cells. J. Virol. 80:1098-1109.
31. Jiang, S.-Y., D. M. Wolf, J. M. Yingling, C. Chang, and V. C. Jordan. 1992. An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol. Mol. Cell. Endocrinol. 90:77-86.
32. Jones, R. J., S. Dickerson, P. M. Bhende, H.-J. Delecluse, and S. C. Kenney. 2007. Epstein-Barr virus lytic infection induces retinoic acid-responsive genes through induction of a retinol metabolizing enzyme, DHRS9. J. Biol. Chem. 282:8317-8324.
33. Kenney, S. C., J. Kamine, E. Holley-Guthrie, J.-C. Lin, E.-C. Mar, and J. Pagano. 1989. The Epstein-Barr virus (EBV) BZLF1 immediate-early gene product differentially affects latent versus productive EBV promoters. J. Virol. 63:1729-1736.
34. Kieff, E., and A. B. Rickinson. 2001. Epstein-Barr virus and its replication, p. 2511-2552. In D. M. Knipe, P. M. Howley, D. E. Griffin, et al. (ed.), Fields Virology, 4th ed. Lippincott-Raven Publishers, Philadelphia, PA.
35. Kraus, R. J., S. J. Mirocha, H. M. Stephany, J. R. Puchalski, and J. E. Mertz. 2001. Identification of a novel element involved in regulation of the lytic switch BZLFI gene promoter of Epstein-Barr virus. J. Virol. 75:867-877.
36. Kraus, R. J., J. G. Perrigoue, and J. E. Mertz. 2003. ZEB negatively regulates the lytic-switch BZLF1 gene promoter of Epstein-Barr virus. J. Virol. 77:199-207.
37. Lemaigre, F. P., C. I. Ace, and M. R. Green. 1993. The cAMP response element binding protein, CREB, is a potent inhibitor of diverse transcriptional activators. Nucleic Acids Res. 21:2907-2911.
38. Li, Q. X., L. S. Young, and G. Niedobitek. 1992. Epstein-Barr virus infection and replication in a human epithelial cell system. Nature 356: 347-350.
39. Liang, L.-C., J.-L. Chen, Y.-P. P. Hsu, J. T. Ou, and Y.-S. Chang. 2002. Epstein-Barr virus BZLFI gene is activated by transforming growth factor-β through cooperativity of Smads and c-Jun/c-Fos proteins. J. Biol. Chem. 277:23345-23357.
40. Lieberman, P. M., J. M. Hardwick, J. Sample, G. S. Hayward, and S. D. Hayward. 1990. The Zta transactivator involved in induction of lytic cycle gene expression in Epstein-Barr virus-infected lymphocytes binds to both AP-1 and ZRE sites in target promoter and enhancer regions. J. Virol. 64:1143-1155.
41. Liu, P., S. Liu, and S. H. Speck. 1998. Identification of a negative cis element within the ZII domain of the Epstein-Barr virus lytic switch BZLF1 gene promoter. J. Virol. 72:8230-8239.
42. Liu, S., P. Liu, A. Borras, T. Chatila, and S. H. Speck. 1997. Cyclosporin A-sensitive induction of the Epstein-Barr virus lytic switch is mediated via a novel pathway involving a MEF2 family member. EMBO J. 16:143-153.
43. MacCallum, P., L. Karimi, and L. J. Nicholson. 1999. Definition of the transcription factors which bind the differentiation responsive element of the Epstein-Barr virus BZLF1 Z promoter in human epithelial cells. J. Gen. Virol. 80:1501-1512.
44. Mentzer, S. J., J. Fingeroth, J. J. Reilly, S. P. Perrine, and D. V. Faller. 1998. Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr virus (EBV)-associated lymphoma. Blood Cells Mol. Dis. 24:114-123.
45. Mentzer, S. J., S. P. Perrine, and D. V. Faller. 2001. Epstein-Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate. Transplant Infect. Dis. 3:177-185.
46. Mitchell, T., and B. Sugden. 1995. Stimulation of NF-κB-mediated transcription by mutant derivatives of the latent membrane protein of Epstein-Barr virus. J. Virol. 69:2968-2976.
47. Moore, S. M., J. S. Cannon, Y. C. Tanhehco, F. M. Hamzeh, and R. F. Ambinder. 2001. Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues. Antimicrob. Agents Chemother. 45:2082-2091.
48. Postigo, A. A. 2003. Opposing functions of ZEB proteins in the regulation of the TGFβ/BMP signaling pathway. EMBO J. 22:2443-2452.
49. Postigo, A. A., and D. C. Dean. 1997. ZEB, a vertebrate homolog of Drosophila Zfh-1, is a negative regulator of muscle differentiation. EMBO J. 16:3935-3943.
50. Postigo, A. A., and D. C. Dean. 1999. Independent repressor domains in ZEB regulate muscle and T-cell differentiation. Mol. Cell. Biol. 19:7961-7971.
51. Postigo, A. A., J. L. Depp, J. J. Taylor, and K. L. Kroll. 2003. Regulation of Smad signaling through a differential recruitment of coactivators and corepressors by ZEB proteins. EMBO J. 22:2453-2462.
52. Ragoczy, T., L. Heston, and G. Miller. 1998. The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes. J. Virol. 72:7978-7984.
53. Rickinson, A. B., and E. Kieff. 2001. Epstein-Barr virus, p. 2575-2627. In D. M. Knipe, P. M. Howley, D. E. Griffin, et al. (ed.), Fields virology, 4th ed. Lippincott-Raven Publishers, Philadelphia, PA.
54. Rooney, C. M., D. T. Rowe, T. Ragot, and P. J. Farrell. 1989. The spliced BZLF1 gene of Epstein-Barr virus (EBV) transactivates an early EBV promoter and induces the virus productive cycle. J. Virol. 63:3109-3116.
55. Ryan, J. L., H. Fan, S. L. Glaser, S. A. Schichman, N. Raab-Traub, and M. L. Gulley. 2004. Epstein-Barr virus quantitation by real-time PCR targeting multiple gene segments: a novel approach to screen for the virus in paraffin-embedded tissue and plasma. J. Mol. Diagn. 4:378-385.
56. Sixbey, J. W. 1989. Epstein-Barr virus and epithelial cells. In G. Klein (ed.), Advances in viral oncology, p. 187-202. Raven Press, New York, NY.
57. Sixbey, J. W., J. G. Nedrud, N. Raab-Traub, R. A. Hanes, and J. S. Pagano. 1984. Epstein-Barr virus replication in oropharyngeal epithelial cells. N. Engl. J. Med. 310:1225-1230.
58. Stein, B., A. S. Baldwin, D. W. Ballard, W. C. Greene, P. Angel, and P. Herrlich. 1993. Cross-coupling of the NF-κB p65 and Fos/Jun transcription factors produces potentiated biological function. EMBO J. 12:3879-3891.
59. Stewart, S., C. W. Dawson, K. Takada, J. Curnow, C. A. Moody, J. W. Sixbey, and L. S. Young. 2004. Epstein-Barr virus-encoded LMP2A regulates viral and cellular gene expression by modulation of the NF-κB transcription factor pathway. Proc. Natl. Acad. Sci. USA 101:15730-15735.
60. Takada, K. 1984. Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt lymphoma lines. Int. J. Cancer 33:27-32.
61. Wang, Y.-C. J., J.-M. Huang, and E. A. Montalvo. 1997. Characterization of proteins binding to the ZII element in the Epstein-Barr virus BZLF1 promoter: transactivation by ATF1. Virology 227:323-330.
62. Westphal, E.-M., A. Mauser, J. Swenson, M. G. Davis, C. L. Talarico, and S. C. Kenney. 1999. Induction of lytic Epstein-Barr virus (EBV) infection in EBV-associated malignancies using adenovirus vectors in vitro and in vivo. Cancer Res. 59:1485-1491.
63. Westphal, E. M., W. Blackstock, W. Feng, B. Israel, and S. C. Kenney. 2000. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies. Cancer Res. 60:5781-5788.
64. Yang, L., S. Maruo, and K. Takada. 2000. CD21-mediated entry and stable infection by Epstein-Barr virus in canine and rat cells. J. Virol. 74:10745-10751.
65. Yasui, D. H., T. Genetta, T. Kadesch, T. M. Williams, S. L. Swain, L. V. Tsui, and B. T. Huber. 1998. Transcriptional repression of the IL-2 gene in Th cells by ZEB. J. Immunol. 160:4433-4440.
66. Yeung, W. M., Y. S. Zong, C. T. Chiu, K. H. Chan, J. S. Sham, D. T. Choy, and M. H. Ng. 1993. Epstein-Barr virus carriage by nasopharyngeal carcinoma in situ. Int. J. Cancer 53:746-750.
67. Zalani, S., E. Holley-Guthrie, and S. Kenney. 1996. Epstein-Barr viral latency is disrupted by the IE BRLF1 protein through a cell-specific mechanism. Proc. Natl. Acad. Sci. USA 93:9194-9199.